This article explores the potential association between co-administration of vancomycin and piperacillin-tazobactam with the development of acute kidney injury (AKI) when compared with vancomycin and other beta lactam antibiotics or vancomycin monotherapy. Based upon available evidence, the combination of vancomycin and piperacillin-tazobactam at therapeutic dosages correlates with increased incidence of AKI when compared to vancomycin and cefepime, vancomycin and meropenem, and vancomycin monotherapy. The majority of these trials are retrospective and most do not evaluate patient outcomes. There remains a need for large, prospective, randomized, controlled trials to determine a causative relationship and assess clinical ramifications with the concomitant use of vancomycin and piperacillin-tazobactam and development of AKI.
INTRODUCTION
The combination of antipseudomonal β-lactams and an agent active against methicillin-resistant Staphylococcus aureus (MRSA) is often indicated for the empiric treatment of severe infections, such as diabetic foot infections, sepsis, and the treatment of hospital acquired pneumonia/ventilator acquired pneumonia. An antibiotic regimen that consists of these agents provides extensive coverage of both Gram-positive and Gram-negative organisms. Two of the most commonly utilized agents in these situations are vancomycin and piperacillin-tazobactam. Recently, there has been concern that this combination of antimicrobials contributes to an elevated risk for development of acute kidney injury (AKI). Vancomycin has been shown to cause acute tubular necrosis and piperacillin-tazobactam has been shown to cause acute interstitial nephritis 1 , but determining the true incidence is difficult due to the necessity of renal biopsy for confirmation of diagnosis 2 . This article seeks to review the reported association between co-administration of vancomycin and piperacillin-tazobactam and the development of AKI. 8 , and the Vancomycin Consensus Guideline definition 9 . Patients had to have been taking the combination antibiotic therapy for greater than forty-eight hours in order to be included in this trial. Patients were excluded from this trial if they had a baseline serum creatinine greater than 1.2 mg/dL or if they required renal replacement therapy at the time combination therapy was initiated. There were 329 patients who received vancomycin and piperacillin-tazobactam versus 803 patients that received vancomycin and cefepime. Of the 803 patients that received vancomycin and cefepime, 279 were matched with someone from the other treatment group and included in the trial. The rate of AKI development, based on the RIFLE criteria, was greater in the vancomycin and piperacillin-tazobactam group (81 patients, 29%) than the vancomycin and cefepime group (31, 11.1%) (HR = 4.0, 95% CI, 2.6-6.2, p < 0.0001). Per the AKIN criteria (stage 1: 48 patients vs. 20 patients, stage 2: 21 patients vs. 8 patients, and stage 3: 20 patients vs. 11 patients), rates of AKI were higher in the vancomycin and piperacillintazobactam group (32%) than the vancomycin and cefepime group (14%) (HR 3.5; 95% CI, 2.3-5.2; p < 0.0001). And finally, per Vancomycin Consensus Guidelines, rates of AKIwere also higher in the vancomycin and piperacillin-tazobactam group versus the vancomycin and cefepime group (24% versus 8.2%, respectively) (HR 4.4; 95% CI, 2.7-7.3; p < 0.0001). The median length of stay after initiation of combination therapy was longer for vancomycin and piperacillin-tazobactam patients compared to vancomycin and cefepime patients (8 days vs. 6 days; p = 0.01). There was no significant difference in mortality rates between the groups (16 deaths versus 24 deaths). This trial demonstrated that concomitant vancomycin and piperacillin-tazobactam correlated with a higher incidence of AKI development when compared to vancomycin and cefepime. The authors should be commended for stratifying AKI and utilizing different criteria for diagnosis. Additionally, the evaluation of mortality and length of stay provides insight into the overall impact on patient outcomes.
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CONCLUSION
Based upon available evidence, the combination of vancomycin and piperacillin-tazobactam at therapeutic dosages has shown a correlation with increased incidence of AKI when compared to vancomycin and cefepime, vancomycin and meropenem, or vancomycin monotherapy. However, these trials were not without limitations. It is important to note the largest study and the studies included in the meta-analysis were observational, and therefore conclusions should be drawn accordingly.
The results of these studies should also be evaluated in the context of their varying threshold of AKI categorization. As to lend generalizability, future results should be stratified for the severity of AKI and patient progression to hemodialysis should be assessed. Furthermore, due to the low threshold of AKI, there may have been patients identified as having an AKI that did not have clinically significant implications on outcomes.
In current practice, there is a role for empiric broad-spectrum antibiotics and the use of vancomycin and piperacillintazobactam should not be avoided when clinically indicated, especially in patients with adequate baseline kidney function. Practicing sound stewardship by only using It is also important to make health care providers aware of this potential outcome and consideration should be given to patients identified as high risk for kidney problems. Furthermore, this correlation should be considered when developing a hospital formulary, as often the empiric use of vancomycin and piperacillin-tazobactam is recommended for broad-spectrum coverage.
As a result, there remains a need for large, prospective, randomized, controlled trials to determine a causative relationship and evaluate patient outcomes with the concomitant use of vancomycin and piperacillin-tazobactam and development of AKI. Exploring the additive nephrotoxic effects may elucidate the mechanism through which vancomycin and piperacillintazobactam interact and lead to better identification of at-risk patients.
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